Thymidylate kinase: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{STRUCTURE_1e99| PDB=1e99 | SIZE=350| SCENE= |right|CAPTION=Human thymidylate kinase complex with HIV prodrug AZTP, ADP (stick model) and Mg+2 ion (green) [[1e99]] }} | {{STRUCTURE_1e99| PDB=1e99 | SIZE=350| SCENE= |right|CAPTION=Human thymidylate kinase complex with HIV prodrug AZTP, ADP (stick model) and Mg+2 ion (green) [[1e99]] }} | ||
'''Thymidylate kinase''' (TMK) catalyzes the conversion of thymidine-5’-phosphate (dTMP) and ATP to thymidine-5’-diphosphate and ADP. TMK is important for DNA synthesis. Inhibitors of TMK include bisubstrate compounds of the type TP(n)X where P(n) are the number of phosphoryl groups and X is the nucleoside moiety of the acceptor. The TMK inhibitor azido-dTMP (AZTP) is an HIV AZT prodrug metabolite. | '''Thymidylate kinase''' (TMK) catalyzes the conversion of thymidine-5’-phosphate (dTMP) and ATP to thymidine-5’-diphosphate and ADP. TMK is important for DNA synthesis. Inhibitors of TMK include bisubstrate compounds of the type TP(n)X where P(n) are the number of phosphoryl groups and X is the nucleoside moiety of the acceptor. The TMK inhibitor azido-dTMP (AZTP) is an HIV AZT prodrug metabolite. | ||